InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,200.80
(
-0.33%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
-0.66%
)
Bitcoin
60,154.55
(
-2.36%
)
Post# of 252426
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119954
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 96482

Thursday, 05/27/2010 5:39:16 PM

Thursday, May 27, 2010 5:39:16 PM

Post# of 252426
Re: Generic Thalomid (lack thereof)

Why the turnabout, IYO? In Dec 2006, I posted this (#msg-15523310):

Barr is somewhat different from other generic-drug companies—their self-proclaimed raison d’etre is to pursue challenges in cases that other companies won’t touch. CEO Bruce Downey singled out drugs with a risk-management program as one facet of the business strategy.

Could the explanation be that Teva’s new management team has become more conservative in old age? This does not exactly ring true, but I don’t have a better explanation handy.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up